- A conversation with Jason Luoma, PhD
The potential of psychedelics in treating anxiety disorders is capturing increasing attention from researchers and clinicians worldwide. With a groundbreaking clinical trial investigating MDMA-assisted therapy for Social Anxiety Disorder, clinical psychologist Jason Luoma has been a pioneering figure in exploring how psychedelics might transform our approach to anxiety. But how can psychedelic treatments extend beyond MDMA, and what role might therapies like Acceptance and Commitment Therapy (ACT) play in managing anxiety and avoidance?
Tonight's conversation
Jason Luoma, researcher, clinician, and ACT expert, joins clinical psychologist Filip Bromberg for an engaging discussion on the role of psychedelics in treating anxiety disorders. They will explore Jason's recent MDMA-assisted therapy trial for Social Anxiety Disorder, discuss broader psychedelic research for anxiety, and delve into how ACT provides a valuable psychological framework for understanding and addressing anxiety-related avoidance. How can clinicians integrate psychedelics into their practice responsibly, and what implications does this have for future mental health treatments? Join us for a thought-provoking dialogue about the intersection of psychedelics, anxiety disorders, and therapeutic innovation.
Date & Time: September 16th 19.00 CEST
Deepen Your Learning
Interested in further integrating ACT into your clinical practice with psychedelics? Jason Luoma will also be leading an immersive full-day workshop on September 25th in Stockholm. This workshop offers clinicians a comprehensive, practical exploration of how ACT principles can enrich psychedelic-assisted therapy, from preparation to integration, with an emphasis on clinical applications, ethical practice, and experiential exercises.
Curious to learn more about the person leading the workshop?
About Lavin
This webinar is brought to you by Borealis Psychedelic Science Summit, in collaboration with the Swedish Psychedelic Education Company Lavin.
Lavin is a new platform for education and training, integrating scientific and clinical expertise with harm-reduction principles to support the safe and ethical use of psychedelics. Lavin offers high-quality courses for healthcare professionals with a uniquely Swedish perspective. Its mission is to build a professional community and a solid foundation for the future implementation of psychedelic-assisted treatments in Sweden.
If you have any questions, please contact [email protected].
